Eli Lilly reports 6.34M-share Aktis Oncology stake

Eli Lilly & Co filed an initial ownership report showing a significant equity position in Aktis Oncology, Inc. (AKTS).

Accepted by SEC EDGAR 01/15/2026 - 06:01 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Eli Lilly & Co filed an initial ownership report showing a significant equity position in Aktis Oncology, Inc. (AKTS). As of 01/12/2026, Eli Lilly beneficially owned 6,344,114 shares of Aktis Oncology common stock, reported as a direct holding and establishing it as a 10% owner of the company. The filing does not list any derivative securities, so the disclosed stake consists solely of common shares. This type of report is a standard regulatory disclosure of a large shareholder’s position.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider ELI LILLY & Co

Role 10% Owner

Type	Security	Shares	Price	Value
Holding	Common Stock	--	--	--

Holdings: Common Stock — 6,344,114 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Eli Lilly (LLY) report in this Aktis Oncology (AKTS) Form 3?

Eli Lilly & Co reported its initial beneficial ownership position in Aktis Oncology, Inc., disclosing a large holding of the companys common stock.

How many Aktis Oncology shares does Eli Lilly own according to the Form 3?

The Form 3 shows Eli Lilly beneficially owning 6,344,114 shares of Aktis Oncology common stock.

What is Eli Lillys relationship to Aktis Oncology based on this filing?

Eli Lilly is identified as a 10% owner of Aktis Oncology, meaning it holds at least ten percent of the companys outstanding common stock.

Is Eli Lillys Aktis Oncology ownership reported as direct or indirect?

The ownership of the 6,344,114 common shares is reported as direct (D) beneficial ownership.

Are any derivative securities reported for Eli Lilly in this Form 3?

No. The table for derivative securities shows no entries, indicating that only common stock holdings are reported in this filing.

What is the effective date of Eli Lillys reported ownership in Aktis Oncology?

The date of the event requiring the statement is listed as 01/12/2026, which is the reference date for the reported share ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

ELI LILLY & Co

(Last) (First) (Middle)

LILLY CORPORATE CENTER

(Street)

INDIANAPOLIS IN 46285

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/12/2026

3. Issuer Name and Ticker or Trading Symbol
Aktis Oncology, Inc. [ AKTS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	6,344,114	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Christopher Anderson, Vice President, Leader of Corporate Securities and Assistant Corporate Secretary	01/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.